

SUPPLEMENTAL TABLE LEGENDS

Table SI. Search strategy conducted the 18th of October 2025

("Amlitelimab" OR "KY1005" OR "SAR445229")
OR
("Rocatinlimab" OR "AMG 451" OR "KHK4083")
OR
("Telazorlimab" OR "ISB 830" OR "GBR 830" OR "GBR-830")
AND
("phase 2" OR "phase II" OR "phase 3" OR "phase III")
AND
("atopic dermatitis" OR "atopic eczema")

Table SII. General characteristics of the OX40/OX40L inhibitors

Drug	Antibody design	Main target	Affinity
Amlitelimab	Fully human, IgG4 monoclonal (Non-depleting)	OX40L	0.07 nM[S1]
Rocatinlimab	Fully human, afucosylated IgG1 monoclonal (Enhanced ADCC)	OX40	3.00 nM[S2]
Telazorlimab	Humanized IgG1 monoclonal (ADCC)	OX40	59.00 nM[S2]

ADCC: Antibody-Dependent Cellular Cytotoxicity; nM: Nanomolar

Table SIII. General characteristics of the included studies

OX40/OX40L	Trial	Phase	Drug dose	Concomitant treatment	Evaluation time point [weeks]	OX40/OX40L patients [n]	OX40/OX40L males [n]	OX40/OX40L age [mean $\pm$ SD]	Placebo patients [n]	Placebo males [n]	Placebo age [mean $\pm$ SD]
Amlitelimab (OX40L)	(NCT03754309)[2]	2a	200 mg, 500 mg	No	16	59	32	34.35 $\pm$ 12.30	29	19	32.10 $\pm$ 10.80
	STREAM-AD[4] (NCT05131477)	2b	250 mg Q4W + LD, 250 mg Q4W, 125 mg Q4W, 62.5 mg Q4W	Topical rescue therapy	24	311	170	38.15 $\pm$ 14.63	78	49	36.40 $\pm$ 13.10
Rocatinlimab (OX40)	(NCT03703102)[1]	2b	150 mg Q4W, 600 mg Q4W, 300 mg Q2W, 600	No	18	216	127	37.70 $\pm$ 14.78	57	31	38.70 $\pm$ 14.40

			mg Q2W								
	ROCKET- HORIZON[6] (NCT05651711)	3	300 mg	Rescue therapy	24	544	295	37.80 ± 14.60	180	102	40.40 ± 15.60
	ROCKET- IGNITE[6] (NCT05398445)	3	150 mg, 300 mg	Rescue therapy	24	540	325	38.50 ± 15.40	218	122	37.10 ± 14.00
	ROCKET- SHUTTLE[7] (NCT05724199)	3	150 mg, 300 mg	Mild to medium steroids and TCI	24	516	308	38.80 ± 14.80	230	135	37.50 ± 14.70
	(NCT02683928)[5]	2a	10 mg/kg	Emollients and mild steroids	12	46	21	36.20 ± 13.40	16	11	40.40 ± 15.10
Telazorlimab (OX40)	(NCT03568162)[3]	2b	300 mg Q2W, 600 mg Q2W, 75 mg Q4W, 300 mg Q4W	No	16	306	152	38.28 ± 14.53	154	63	36.15 ± 13.45

LD: Loading Dose; N: Number; Q2W: Every 2 weeks; Q4W: Every 4 weeks; TCI: Topical Calcineurin Inhibitors

Table SIV. Risk of Bias Assessment

Study	D1: Randomization Process	D2: Deviations from Intended Interventions	D3: Missing Outcome Data	D4: Measurement of the Outcome	D5: Selection of the Reported Result	Overall Risk
Guttman-Yassky (2019)[5]	Low	Low	Some concerns	Low	Low	Some concerns
Guttman-Yassky (2023)[1]	Low	Low	Some concerns	Low	Low	Some concerns
Guttman-Yassky (2025)[6]	Low	Low	Low	Low	Low	Low
Rewerska (2024)[3]	Low	Low	Low	Low	Low	Low
Simpson (2025)[7]	High	High	High	Some concerns	High	High
Weidinger (2023)[2]	Low	Low	Low	Low	Low	Low
Weidinger (2025)[4]	Low	Low	Low	Low	Low	Low

[illegible]

	ROCKET-SHUTTLE[7] (NCT05724199)				(71.5%)	(3.7%)	(1.4%)										
		Placebo		230	155 (67.4%)	2 (0.9%)	1 (0.4%)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Telazorlimab (OX40)		Telazorlimab	12	46	29 (63.0%)	NA	NA	NA	6 (13.0%)	NA	NA	2 (4.3%)	0 (0.0%)	6 (13.0%)	4 (8.7%)	NA	4 (8.7%)
		Placebo		16	10 (62.5%)	NA	NA	NA	2 (12.5%)	NA	NA	1 (6.3%)	2 (12.5%)	4 (25.0%)	2 (12.5%)	NA	2 (12.5%)
		Telazorlimab	16	306	202 (66.0%)	8 (2.6%)	4 (1.3%)	NA	63 (20.6%)	NA	NA	6 (2.0%)	NA	18 (5.9%)	25 (8.2%)	NA	21 (6.9%)
		Placebo		154	93 (60.4%)	2 (1.3%)	3 (1.9%)	NA	29 (18.8%)	NA	NA	1 (0.6%)	NA	7 (4.5%)	14 (9.1%)	NA	12 (7.8%)

AEs: Adverse Events; GI: Gastrointestinal; N: Number; NA: Not Available

SUPPLEMENTAL REFERENCES

S1. Wickman G, Kang BH, Meinke J, Raso S, Oh J, Shaheen H, et al. Preclinical potency, affinity, and pharmacokinetics of APG990, a half-life extended antibody against OX40L. Poster presented at: 2025 Winter Clinical Dermatology Conference; 2025 Feb 14-19; Hawaii, USA.

S2. Biris N, Macoin J, Carretero L, Perez C, Zhao C. Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody. Poster presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024; 2024 May 31 - Jun 3; Valencia, Spain.